

A 6-8-74
17. An effervescent pharmaceutical formulation for the sustained and controlled oral administration of a pharmaceutically effective amount of a combination of a calcium channel blocker and a narcotic analgesic, said formulation comprising microcapsules in which the drug is entrapped in a biodegradable polymer.

18. The pharmaceutical formulation of Claim 17, wherein the calcium channel blocker is nifedipine.

19. The pharmaceutical formulation of Claim 17, wherein the calcium channel blocker is diltiazem.

20. An effervescent pharmaceutical formulation for the sustained and controlled oral administration of a pharmaceutically effective amount of a combination of a ACE inhibitor and a narcotic analgesic, said formulation comprising microcapsules in which the drug is entrapped in a biodegradable polymer. *as*

REMARKS

Upon entry of the foregoing amendments, there will be 20 claims pending. Claims 17-20 have been added. Claims 3-5, 8-10, 12 and 14-16 have been amended to remove multiple dependencies. Support for new Claims 17-20 can be found throughout the specification, such as in original Claim 1. Thus, applicants submit that no new matter has been added by these amendments.

A check in the amount of \$958.00 is attached as required for the National Fee, including the added claims. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0670.

Pursuant to the above amendments and remarks, consideration and allowance of the pending application is believed to be warranted. The Examiner is invited and

encouraged to directly contact the undersigned if such contact may enhance the efficient prosecution of this application to issue.

Respectfully submitted,



Mary L. Severson, Ph.D.
Registration No. 34,927

ELAN PHARMACEUTICAL
RESEARCH CORPORATION
1300 Gould Drive
Gainesville, GA 30504
Telephone: (770) 534-8239

I hereby certify that this correspondence is being deposited with the United States Postal Service as **Express Mail Invoice No. EH 608540192 US**, in an envelope addressed to:

Commissioner of Patents
and Trademarks
Washington, D.C. 20231

on this 4th day of October 1996.


Pamela Scarbrough

Oct. 4/1996
Date